Compare IPHA & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | EDF |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 154.9M |
| IPO Year | 2019 | N/A |
| Metric | IPHA | EDF |
|---|---|---|
| Price | $1.96 | $4.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 565.0K | 160.6K |
| Earning Date | 09-17-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,839,695.00 | N/A |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $3.51 |
| 52 Week High | $3.51 | $5.50 |
| Indicator | IPHA | EDF |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 43.99 |
| Support Level | $1.85 | $4.88 |
| Resistance Level | $2.01 | $4.95 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 69.64 | 53.33 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.